• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Fluidigm Files Patent Infringement Against IONpath

    Jocelyn Aspa
    Sep. 10, 2019 09:06AM PST
    Biotech Investing

    Fluidigm (NASDAQ:FLDM) has announced it has filed a legal suit in the United States District Court for the Northern District of California against IONpath. As quoted in the press release: In the complaint, Fluidigm alleges that IONpath’s MIBI Technology infringes Fluidigm’s U.S. Patent Nos. 10,180,386 and 10,072,104. The lawsuit seeks damages and injunctive relief requiring …

    Fluidigm (NASDAQ:FLDM) has announced it has filed a legal suit in the United States District Court for the Northern District of California against IONpath.

    As quoted in the press release:

    In the complaint, Fluidigm alleges that IONpath’s MIBI Technology infringes Fluidigm’s U.S. Patent Nos. 10,180,386 and 10,072,104. The lawsuit seeks damages and injunctive relief requiring IONpath to stop selling its infringing MIBI Technology.

    “Fluidigm has made substantial investments in the research and development of its CyTOF® technology,” said Chris Linthwaite, President and CEO of Fluidigm. “This lawsuit is aimed at protecting those investments and ensuring that the emerging Imaging Mass Cytometry™ market remains a competitive industry for the benefit of the many research customers who are driving new insights across a broad spectrum of diseases, including cancer and autoimmune and chronic inflammatory conditions. The legal action we are taking demonstrates our commitment to protecting our investments and defending our proprietary rights by enforcing our patents against those who unfairly use our proprietary technology.”

    Click here to read the full press release.

    nasdaq:fldm
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Test tubes.

    Biotech Market Forecast: Top Trends for Biotech in 2025

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES